Theratechnologies (TSE:TH) has released an update.
Theratechnologies has advanced to an increased dose level in their Phase 1 trial of sudocetaxel zendusortide for treating advanced ovarian cancer after a Medical Review Committee sanctioned the dose escalation following positive safety evaluations. The trial, integral to determining the optimal dose for this novel therapy, has successfully enrolled one patient at the new dose, with the aim to address the pressing needs of patients with platinum-resistant ovarian cancer. This progression marks a significant milestone in the development of sudocetaxel zendusortide, a first-of-its-kind therapy targeting the SORT1 receptor expressed in various aggressive cancers.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
